188 related articles for article (PubMed ID: 11698657)
1. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.
Persson E; Kjalke M; Olsen OH
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13583-8. PubMed ID: 11698657
[TBL] [Abstract][Full Text] [Related]
2. Evolutionary conservation of the allosteric activation of factor VIIa by tissue factor in lamprey.
Beeler DL; Aird WC; Grant MA
J Thromb Haemost; 2018 Apr; 16(4):734-748. PubMed ID: 29418058
[TBL] [Abstract][Full Text] [Related]
3. Activation loop 3 and the 170 loop interact in the active conformation of coagulation factor VIIa.
Persson E; Olsen OH
FEBS J; 2009 Jun; 276(11):3099-109. PubMed ID: 19490111
[TBL] [Abstract][Full Text] [Related]
4. Prevention of beta strand movement into a zymogen-like position does not confer higher activity to coagulation factor VIIa.
Olsen OH; Nielsen PF; Persson E
Biochemistry; 2004 Nov; 43(44):14096-103. PubMed ID: 15518559
[TBL] [Abstract][Full Text] [Related]
5. Allosteric activation of coagulation factor VIIa.
Persson E; Olsen OH
Front Biosci (Landmark Ed); 2011 Jun; 16(8):3156-63. PubMed ID: 21622226
[TBL] [Abstract][Full Text] [Related]
6. Factor VII mutant V154G models a zymogen-like form of factor VIIa.
Toso R; Bernardi F; Tidd T; Pinotti M; Camire RM; Marchetti G; High KA; Pollak ES
Biochem J; 2003 Feb; 369(Pt 3):563-71. PubMed ID: 12358603
[TBL] [Abstract][Full Text] [Related]
7. Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement.
Persson E; Bak H; Østergaard A; Olsen OH
Biochem J; 2004 Apr; 379(Pt 2):497-503. PubMed ID: 14686879
[TBL] [Abstract][Full Text] [Related]
8. Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity.
Sorensen AB; Madsen JJ; Svensson LA; Pedersen AA; Østergaard H; Overgaard MT; Olsen OH; Gandhi PS
J Biol Chem; 2016 Feb; 291(9):4671-83. PubMed ID: 26694616
[TBL] [Abstract][Full Text] [Related]
9. The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry.
Rand KD; Andersen MD; Olsen OH; Jørgensen TJ; Ostergaard H; Jensen ON; Stennicke HR; Persson E
J Biol Chem; 2008 May; 283(19):13378-87. PubMed ID: 18343822
[TBL] [Abstract][Full Text] [Related]
10. Beating tissue factor at its own game: Design and properties of a soluble tissue factor-independent coagulation factor VIIa.
Sorensen AB; Tuneew I; Svensson LA; Persson E; Østergaard H; Overgaard MT; Olsen OH; Gandhi PS
J Biol Chem; 2020 Jan; 295(2):517-528. PubMed ID: 31801825
[TBL] [Abstract][Full Text] [Related]
11. Structural modulation of factor VIIa by full-length tissue factor (TF
Prasad R; Sen P
J Biomol Struct Dyn; 2018 Feb; 36(3):621-633. PubMed ID: 28150568
[TBL] [Abstract][Full Text] [Related]
12. Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor.
Persson E; Nielsen LS; Olsen OH
Biochemistry; 2001 Mar; 40(11):3251-6. PubMed ID: 11258943
[TBL] [Abstract][Full Text] [Related]
13. Tissue factor activates allosteric networks in factor VIIa through structural and dynamic changes.
Madsen JJ; Persson E; Olsen OH
J Thromb Haemost; 2015 Feb; 13(2):262-7. PubMed ID: 25403348
[TBL] [Abstract][Full Text] [Related]
14. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis.
Norledge BV; Petrovan RJ; Ruf W; Olson AJ
Proteins; 2003 Nov; 53(3):640-8. PubMed ID: 14579355
[TBL] [Abstract][Full Text] [Related]
15. Large enhancement of functional activity of active site-inhibited factor VIIa due to protein dimerization: insights into mechanism of assembly/disassembly from tissue factor.
Stone MD; Harvey SB; Martinez MB; Bach RR; Nelsestuen GL
Biochemistry; 2005 Apr; 44(16):6321-30. PubMed ID: 15835921
[TBL] [Abstract][Full Text] [Related]
16. Disulfide locked variants of factor VIIa with a restricted beta-strand conformation have enhanced enzymatic activity.
Maun HR; Eigenbrot C; Raab H; Arnott D; Phu L; Bullens S; Lazarus RA
Protein Sci; 2005 May; 14(5):1171-80. PubMed ID: 15840825
[TBL] [Abstract][Full Text] [Related]
17. A thrombophilic allele of clotting Factor VII/VIIa promoting recurrent pulmonary emboli, clinical details, and a structural model of the altered protein: a case report.
Newman K; Daldal F; Dancis A
J Med Case Rep; 2023 Apr; 17(1):161. PubMed ID: 37055848
[TBL] [Abstract][Full Text] [Related]
18. Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity.
Persson E; Bak H; Olsen OH
J Biol Chem; 2001 Aug; 276(31):29195-9. PubMed ID: 11389142
[TBL] [Abstract][Full Text] [Related]
19. Substrate recognition by tissue factor-factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X.
Huang Q; Neuenschwander PF; Rezaie AR; Morrissey JH
J Biol Chem; 1996 Sep; 271(36):21752-7. PubMed ID: 8702971
[TBL] [Abstract][Full Text] [Related]
20. A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.
Toso R; Pinotti M; High KA; Pollak ES; Bernardi F
Biochem J; 2002 Apr; 363(Pt 2):411-6. PubMed ID: 11931672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
